up-to-date with a click!
Update february, 2019
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications February 2019

Add on treatments

  1. Ho BL, Lin YJ, Lin SF et al. Statins and the risk of bleeding in patients taking dabigatran. Acta neurologica Scandinavica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30742307
  2. Arbel R, Hammerman A, Azuri J. Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30711247
  3. Sharma A, Sun JL, Lokhnygina Y et al. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30739657
  4. Han SN, Yang WH, Yin JJ et al. Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination. Am J Cardiovasc Drugs 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714088
  5. Kido K, Oyen AA, Beckmann MA, Brouse SD. Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2019; 76:206-210. http://www.ncbi.nlm.nih.gov/pubmed/?term=30689699
  6. Marcum ZA, Walker RL, Jones BL et al. Patterns of antihypertensive and statin adherence prior to dementia: findings from the adult changes in thought study. BMC geriatrics 2019; 19:41. http://www.ncbi.nlm.nih.gov/pubmed/?term=30764775
  7. Li K, Si-Tu J, Qiu J et al. Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study. Cancer management and research 2019; 11:1189-1197. http://www.ncbi.nlm.nih.gov/pubmed/?term=30787638
  8. Ballantyne CM, Manku MS, Bays HE et al. Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. Cardiology and therapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788718
  9. Mohamed AS, Ibrahim WM, Zaki NI et al. Effectiveness of Coelatura aegyptiaca Extract Combination with Atorvastatin on Experimentally Induced Hyperlipidemia in Rats. Evidence-based complementary and alternative medicine : eCAM 2019; 2019:9726137. http://www.ncbi.nlm.nih.gov/pubmed/?term=30713580
  10. Bentz AJ, Netland PJ, Newman WP et al. Comparison of Cardiovascular Outcomes Between Statin Monotherapy and Fish Oil and Statin Combination Therapy in a Veteran Population. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2018; 35:26-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766323
  11. Lee HR, Jo MK, Park KY et al. Anti-TNF effect of combined pravastatin and cilostazol treatment in an in vivo mouse model. Immunopharmacology and immunotoxicology 2019:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714456
  12. Marin-Medina A, Ruiz-Hidalgo G, Ble-Castillo JL et al. Combined Effect of Diosgenin Along with Ezetimibe or Atorvastatin on the Fate of Labelled Bile Acid and Cholesterol in Hypercholesterolemic Rats. International journal of environmental research and public health 2019; 16. http://www.ncbi.nlm.nih.gov/pubmed/?term=30791676
  13. Chan JCM, Ng MH, Wong RSM, Tomlinson B. A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana. Journal of clinical pharmacy and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714173
  14. Lee KR, Midgette Y, Shah R. Fish Oil Derived Omega 3 Fatty Acids Suppress Adipose NLRP3 Inflammasome Signaling in Human Obesity. Journal of the Endocrine Society 2019; 3:504-515. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788452
  15. Cardoso R, Blumenthal RS, Kopecky S et al. How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clinic proceedings 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737057
  16. Andrews GP, Li S, Almajaan A et al. Fixed Dose Combination Formulations: Multi-Layered Platforms Designed for the Management of Cardiovascular Disease. Molecular pharmaceutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30702301
  17. Elamin AFM, Grafton-Clarke C, Wen Chen K et al. Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study. Postgraduate medical journal 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30709868
  18. Rattanachotphanit T, Limwattananon C, Waleekhachonloet O. Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand. Therapeutic advances in drug safety 2019; 10:2042098618820502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728944
  19. Karasek D. Combined lipid-lowering therapy. Vnitr Lek 2019; 64:1177-1184. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704254

Adherence

  1. Marcum ZA, Walker RL, Jones BL et al. Patterns of antihypertensive and statin adherence prior to dementia: findings from the adult changes in thought study. BMC geriatrics 2019; 19:41. http://www.ncbi.nlm.nih.gov/pubmed/?term=30764775
  2. Dowd CM, Tillmann JJ. Therapeutic Interchange From Rosuvastatin to Atorvastatin in a Veteran Population. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2015; 32:20-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766035
  3. Drake B, Grimm DL, Allman J, 2nd. Treatment Failure With Atorvastatin After Change From Rosuvastatin to Atorvastatin. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2015; 32:25-29. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766036
  4. Mulchandani R, Lyngdoh T, Chakraborty P, Kakkar AK. Satisfaction With Statin Treatment Among Adult Coronary Artery Disease Patients: An Experience From a Resource-Constrained Setting. Heart, lung & circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704841
  5. Huynh T, Lecca P, Montigny M et al. Ten-Year Statin Adherence in Survivors of ST-Segment Elevation Myocardial Infarction. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 2018; 25:e63-e77. http://www.ncbi.nlm.nih.gov/pubmed/?term=30725543
  6. Rodriguez F, Maron DJ, Knowles JW et al. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA cardiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30758506
  7. Dansinger M, Williams PT, Superko HR, Schaefer EJ. The importance of cholesterol follow-up testing under current statin treatment guidelines. Prev Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30742874

Atherosclerosis & Imaging

  1. Ogata A, Oho K, Matsumoto N et al. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. Acta neurochirurgica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30729307
  2. Puttarajappa CM, Tevar AD, Hariharan S et al. Screening Coronary Angiography in Patients with Long-Standing Diabetes Mellitus undergoing Kidney Transplant Evaluation. Clinical transplantation 2019:e13501. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776157
  3. Lee SE, Sung JM, Andreini D et al. Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study. European heart journal cardiovascular Imaging 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30789215
  4. Phillips WJ, Johnson C, Law A et al. Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. Int J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30696608
  5. Endo H, Dohi T, Miyauchi K et al. Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737184
  6. Al'Aref SJ, Su A, Gransar H et al. A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography. Journal of cardiovascular computed tomography 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745132
  7. Gill EA, Blaha MJ, Guyton JR. JCL roundtable: Coronary artery calcium scoring and other vascular imaging for risk assessment. J Clin Lipidol 2019; 13:4-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30773212
  8. Sharp AJ, Patel N, Reeves BC et al. Pharmacological interventions for the prevention of contrast-induced acute kidney injury in high-risk adult patients undergoing coronary angiography: a systematic review and meta-analysis of randomised controlled trials. Open heart 2019; 6:e000864. http://www.ncbi.nlm.nih.gov/pubmed/?term=30774964

Atorvastatin/Rosuvastatin

  1. Shek AB, Kurbanov RD, Alieva RB et al. Personalized rosuvastatin therapy in problem patients with partial statin intolerance. Archives of medical sciences. Atherosclerotic diseases 2018; 3:e83-e89. http://www.ncbi.nlm.nih.gov/pubmed/?term=30775595
  2. Kaleli-Durman D, Alp-Yildirim FI, Ozdemir O, Uydes-Dogan BS. Relaxant Effect of Atorvastatin on Isolated Rat Gastric Fundus Strips: Implications for Ca2+ signalling mechanisms. Canadian journal of physiology and pharmacology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30730760
  3. Solberg OG, Stavem K, Ragnarsson A et al. Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30790446
  4. Feng X, Wang C, Gu Z et al. Rosuvastatin Regulates Odontoblast Differentiation by Suppressing NF-kappaB Activation in an Inflammatory Environment. Cellular reprogramming 2019; 21:18-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=30735076
  5. Kelly KE, Jiroutek MR, Lewis K, Zagar B. Assessing Changes in Statin Prescribing Patterns Surrounding the 2013 American College of Cardiology/American Heart Association Lipid Guidelines. Clinical therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30686571
  6. Altunkeser BB, Tuncez A, Ozturk B et al. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome. Coronary artery disease 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30741744
  7. Hwang YC, Jun JE, Jeong IK et al. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30688048
  8. Vesza Z, Pires C, da Silva PM. Statin-related Lichenoid Dermatosis: An Uncommon Adverse Reaction to a Common Treatment. European journal of case reports in internal medicine 2018; 5:000844. http://www.ncbi.nlm.nih.gov/pubmed/?term=30756034
  9. Kim JH, Chung BI. Re: Timu J. Murtola, Hemo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701. European urology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738708
  10. Murtola TJ, Syvala H, Riikonen J. Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701. European urology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738709
  11. Mohamed AS, Ibrahim WM, Zaki NI et al. Effectiveness of Coelatura aegyptiaca Extract Combination with Atorvastatin on Experimentally Induced Hyperlipidemia in Rats. Evidence-based complementary and alternative medicine : eCAM 2019; 2019:9726137. http://www.ncbi.nlm.nih.gov/pubmed/?term=30713580
  12. Haque T, Bhaheetharan S, Khan BV. Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes? Expert review of endocrinology & metabolism 2010; 5:835-837. http://www.ncbi.nlm.nih.gov/pubmed/?term=30780833
  13. Dowd CM, Tillmann JJ. Therapeutic Interchange From Rosuvastatin to Atorvastatin in a Veteran Population. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2015; 32:20-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766035
  14. Drake B, Grimm DL, Allman J, 2nd. Treatment Failure With Atorvastatin After Change From Rosuvastatin to Atorvastatin. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2015; 32:25-29. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766036
  15. Markossian TW, Kramer HJ, Burge NJ et al. Statin use among Veterans with dialysis-dependent chronic kidney disease. Hemodialysis international. International Symposium on Home Hemodialysis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30779455
  16. Marin-Medina A, Ruiz-Hidalgo G, Ble-Castillo JL et al. Combined Effect of Diosgenin Along with Ezetimibe or Atorvastatin on the Fate of Labelled Bile Acid and Cholesterol in Hypercholesterolemic Rats. International journal of environmental research and public health 2019; 16. http://www.ncbi.nlm.nih.gov/pubmed/?term=30791676
  17. Li X, Xiao H, Lin C et al. Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis. International journal of nanomedicine 2019; 14:649-665. http://www.ncbi.nlm.nih.gov/pubmed/?term=30697048
  18. Nenna A, Spadaccio C, Lusini M et al. Preoperative atorvastatin reduces bleeding and blood transfusions in patients undergoing elective isolated aortic valve replacement. Interact Cardiovasc Thorac Surg 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753487
  19. Lee S, Lee HJ, Kang H et al. Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect. Journal of clinical medicine 2019; 8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30754707
  20. Harshman SG, Shea MK, Fu X et al. Atorvastatin Decreases Renal Menaquinone-4 Formation in C57BL/6 Male Mice. The Journal of nutrition 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753659
  21. Kunlamas Y, Areepium N, Ariyachaipanich A, Bunditanukul K. Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention. Journal of pharmacy practice 2019:897190019825915. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776951
  22. Hosseinzadeh A, Bahrampour Juybari K, Kamarul T, Sharifi AM. Protective effects of atorvastatin on high glucose-induced oxidative stress and mitochondrial apoptotic signaling pathways in cultured chondrocytes. Journal of physiology and biochemistry 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30796627
  23. Lee S, Kim DH, Youn YN et al. Rosuvastatin attenuates bioprosthetic heart valve calcification. The Journal of thoracic and cardiovascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738596
  24. Bruder-Nascimento T, Callera GE, Montezano AC et al. Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress. Life sciences 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30721707
  25. Wei H, Yang M, Yu K et al. Atorvastatin Protects Against Cerebral Aneurysmal Degenerative Pathology by Promoting Endothelial Progenitor Cells (EPC) Mobilization and Attenuating Vascular Deterioration in a Rat Model. Medical science monitor : international medical journal of experimental and clinical research 2019; 25:928-936. http://www.ncbi.nlm.nih.gov/pubmed/?term=30710072
  26. Holmes ST, Wang WD, Hou G et al. A new NMR crystallographic approach to reveal the calcium local structure of atorvastatin calcium. Physical chemistry chemical physics : PCCP 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30720026
  27. Masajtis-Zagajewska A, Nowicki M. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Ren Fail 2018; 40:700-709. http://www.ncbi.nlm.nih.gov/pubmed/?term=30741616
  28. Rattanachotphanit T, Limwattananon C, Waleekhachonloet O. Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand. Therapeutic advances in drug safety 2019; 10:2042098618820502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728944
  29. El-Ganainy SO, El-Mallah A, Abdallah D et al. A novel investigation of statins myotoxic mechanism: Effect of atorvastatin on respiratory muscles in hypoxic environment. Toxicology letters 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30735765
  30. Wildes TJ, Grippin A, Fasanya H et al. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. Vaccine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30686636

Basic science

  1. Liu XM, Zhao XM, Deng C et al. Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway. Acta pharmacologica Sinica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728467
  2. Lee H, Lee H, Na CB, Park JB. The effects of simvastatin on cellular viability, stemness and osteogenic differentiation using 3-dimensional cultures of stem cells and osteoblast-like cells. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30729760
  3. Sroda-Pomianek K, Michalak K, Palko-Labuz A et al. Simvastatin Strongly Augments Proapoptotic, Anti-inflammatory and Cytotoxic Activity of Oxicam Derivatives in Doxorubicin-resistant Colon Cancer Cells. Anticancer research 2019; 39:727-734. http://www.ncbi.nlm.nih.gov/pubmed/?term=30711951
  4. Terabe K, Takahashi N, Cobb M et al. Simvastatin promotes restoration of chondrocyte morphology and phenotype. Archives of biochemistry and biophysics 2019; 665:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776329
  5. Sanvee GM, Panajatovic MV, Bouitbir J, Krahenbuhl S. Mechanisms of insulin resistance by simvastatin in C2C12 myotubes and in mouse skeletal muscle. Biochem Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30796916
  6. Sariisik E, Kocak M, Baloglu FK, Severcan F. Interaction of the cholesterol reducing agent simvastatin with zwitterionic DPPC and charged DPPG phospholipid membranes. Biochimica et biophysica acta. Biomembranes 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30707888
  7. Boruta T, Bizukojc M. Application of Aluminum Oxide Nanoparticles in Aspergillus terreus Cultivations: Evaluating the Effects on Lovastatin Production and Fungal Morphology. BioMed research international 2019; 2019:5832496. http://www.ncbi.nlm.nih.gov/pubmed/?term=30733961
  8. Raafat SN. Response to: Letter to the editor: The sole and combined effect of simvastatin and platelet rich fibrin as a filling material in induced bone defect in tibia of albino rats. Bone 2019; 120:534. http://www.ncbi.nlm.nih.gov/pubmed/?term=30711057
  9. Taniguti EH, Ferreira YS, Stupp IJV et al. Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. Brain research bulletin 2019; 146:279-286. http://www.ncbi.nlm.nih.gov/pubmed/?term=30690060
  10. Kaleli-Durman D, Alp-Yildirim FI, Ozdemir O, Uydes-Dogan BS. Relaxant Effect of Atorvastatin on Isolated Rat Gastric Fundus Strips: Implications for Ca2+ signalling mechanisms. Canadian journal of physiology and pharmacology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30730760
  11. Zhang J, Li Q, Wu Y et al. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cell communication and signaling : CCS 2019; 17:15. http://www.ncbi.nlm.nih.gov/pubmed/?term=30786890
  12. Gobel A, Breining D, Rauner M et al. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell death & disease 2019; 10:91. http://www.ncbi.nlm.nih.gov/pubmed/?term=30692522
  13. Tong XK, Trigiani LJ, Hamel E. High cholesterol triggers white matter alterations and cognitive deficits in a mouse model of cerebrovascular disease: benefits of simvastatin. Cell death & disease 2019; 10:89. http://www.ncbi.nlm.nih.gov/pubmed/?term=30692517
  14. Feng X, Wang C, Gu Z et al. Rosuvastatin Regulates Odontoblast Differentiation by Suppressing NF-kappaB Activation in an Inflammatory Environment. Cellular reprogramming 2019; 21:18-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=30735076
  15. Alkreathy HM, Alkhatib MH, Al Musaddi SA et al. Enhanced anti-tumor activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma. Clin Exp Pharmacol Physiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30724380
  16. Mohamed AS, Ibrahim WM, Zaki NI et al. Effectiveness of Coelatura aegyptiaca Extract Combination with Atorvastatin on Experimentally Induced Hyperlipidemia in Rats. Evidence-based complementary and alternative medicine : eCAM 2019; 2019:9726137. http://www.ncbi.nlm.nih.gov/pubmed/?term=30713580
  17. Sun W, Pan R, Song J, Sun H. The effects of simvastatin preconditioning on the expression of caspase-3 after myocardial ischemia reperfusion injury in rats. Experimental and therapeutic medicine 2019; 17:2230-2234. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783483
  18. Vogeli B, Shima S, Erb T, Wagner T. Crystal structure of archaeal HMG-CoA reductase: insights into structural changes of the C-terminal helix of the class-I enzyme. FEBS letters 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30702149
  19. Leggiero E, Labruna G, Iaffaldano L et al. Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice. Gene therapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700805
  20. Lee HR, Jo MK, Park KY et al. Anti-TNF effect of combined pravastatin and cilostazol treatment in an in vivo mouse model. Immunopharmacology and immunotoxicology 2019:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714456
  21. Marin-Medina A, Ruiz-Hidalgo G, Ble-Castillo JL et al. Combined Effect of Diosgenin Along with Ezetimibe or Atorvastatin on the Fate of Labelled Bile Acid and Cholesterol in Hypercholesterolemic Rats. International journal of environmental research and public health 2019; 16. http://www.ncbi.nlm.nih.gov/pubmed/?term=30791676
  22. Li X, Xiao H, Lin C et al. Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis. International journal of nanomedicine 2019; 14:649-665. http://www.ncbi.nlm.nih.gov/pubmed/?term=30697048
  23. Yu XB, Zhang HN, Dai Y et al. Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice. Journal of affective disorders 2019; 245:939-949. http://www.ncbi.nlm.nih.gov/pubmed/?term=30699879
  24. Umeda R, Takanari H, Ogata K et al. Direct free radical scavenging effects of water-soluble HMG-CoA reductase inhibitors. Journal of clinical biochemistry and nutrition 2019; 64:20-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=30705508
  25. Lee S, Lee HJ, Kang H et al. Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect. Journal of clinical medicine 2019; 8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30754707
  26. Lee KR, Midgette Y, Shah R. Fish Oil Derived Omega 3 Fatty Acids Suppress Adipose NLRP3 Inflammasome Signaling in Human Obesity. Journal of the Endocrine Society 2019; 3:504-515. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788452
  27. Hopkins RJ, Young RP. Mevalonate signaling, COPD and cancer: the statins and beyond. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30787037
  28. Harshman SG, Shea MK, Fu X et al. Atorvastatin Decreases Renal Menaquinone-4 Formation in C57BL/6 Male Mice. The Journal of nutrition 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753659
  29. Li Z, Zhang J, Zhang Y, Zuo Z. Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. Journal of pharmaceutical and biomedical analysis 2019; 168:13-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776567
  30. Hosseinzadeh A, Bahrampour Juybari K, Kamarul T, Sharifi AM. Protective effects of atorvastatin on high glucose-induced oxidative stress and mitochondrial apoptotic signaling pathways in cultured chondrocytes. Journal of physiology and biochemistry 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30796627
  31. Lee S, Kim DH, Youn YN et al. Rosuvastatin attenuates bioprosthetic heart valve calcification. The Journal of thoracic and cardiovascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738596
  32. Bruder-Nascimento T, Callera GE, Montezano AC et al. Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress. Life sciences 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30721707
  33. Han Q, Liu Q, Zhang H et al. Simvastatin Improves Cardiac Hypertrophy in Diabetic Rats by Attenuation of Oxidative Stress and Inflammation Induced by Calpain-1-Mediated Activation of Nuclear Factor-kappaB (NF-kappaB). Medical science monitor : international medical journal of experimental and clinical research 2019; 25:1232-1241. http://www.ncbi.nlm.nih.gov/pubmed/?term=30767945
  34. Wei H, Yang M, Yu K et al. Atorvastatin Protects Against Cerebral Aneurysmal Degenerative Pathology by Promoting Endothelial Progenitor Cells (EPC) Mobilization and Attenuating Vascular Deterioration in a Rat Model. Medical science monitor : international medical journal of experimental and clinical research 2019; 25:928-936. http://www.ncbi.nlm.nih.gov/pubmed/?term=30710072
  35. Andrews GP, Li S, Almajaan A et al. Fixed Dose Combination Formulations: Multi-Layered Platforms Designed for the Management of Cardiovascular Disease. Molecular pharmaceutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30702301
  36. Perucha E, Melchiotti R, Bibby JA et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nature communications 2019; 10:498. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700717
  37. Afrasiabi Garekani H, Aftabi SF, Fahimi Nia F et al. Synergistic Effect of Polyethylene Glycol and Superdisintegrant on Dissolution Rate Enhancement of Simvastatin in Pellet Formulation. Pharmaceutical development and technology 2019:1-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776937
  38. Holmes ST, Wang WD, Hou G et al. A new NMR crystallographic approach to reveal the calcium local structure of atorvastatin calcium. Physical chemistry chemical physics : PCCP 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30720026
  39. Tsur A, Kalish F, Burgess J et al. Pravastatin improves fetal survival in mice with a partial deficiency of heme oxygenase-1. Placenta 2019; 75:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30712660
  40. Rosales-Acosta B, Mendieta A, Zuniga C et al. Simvastatin and other inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase of Ustilago maydis (Um-Hmgr) affect the viability of the fungus, its synthesis of sterols and mating. Revista iberoamericana de micologia 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745018
  41. Schulz J, Vollmer C, Truse R et al. Effect of Pravastatin Pretreatment and Hypercapnia on Intestinal Microvascular Oxygenation and Blood Flow During Sepsis. Shock 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30724816
  42. El-Ganainy SO, El-Mallah A, Abdallah D et al. A novel investigation of statins myotoxic mechanism: Effect of atorvastatin on respiratory muscles in hypoxic environment. Toxicology letters 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30735765
  43. Li FL, Wan X, Wang X et al. [Simvastatin prevented myocardium of diabetes rats from apoptosis through inhibition of oxidative stress]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2018; 34:422-426 469. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788922
  44. Wan X, Wang X, Li FL et al. [Protective effect of simvastatin on kidney of rats with diabetes mellitus and the possible mechanism]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2018; 34:313-317. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788938
  45. Huai J, Yang Z, Yi YH, Wang GJ. [Changes of Rheb gene and protein expression in preeclampsia-like mouse model treated with pravastatin]. Zhonghua fu chan ke za zhi 2019; 54:38-43. http://www.ncbi.nlm.nih.gov/pubmed/?term=30695905 

Cancer

  1. Sroda-Pomianek K, Michalak K, Palko-Labuz A et al. Simvastatin Strongly Augments Proapoptotic, Anti-inflammatory and Cytotoxic Activity of Oxicam Derivatives in Doxorubicin-resistant Colon Cancer Cells. Anticancer research 2019; 39:727-734. http://www.ncbi.nlm.nih.gov/pubmed/?term=30711951
  2. Calvillo-Arguelles O, Abdel-Qadir H, Michalowska M et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Can J Cardiol 2019; 35:153-159. http://www.ncbi.nlm.nih.gov/pubmed/?term=30760421
  3. Li K, Si-Tu J, Qiu J et al. Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study. Cancer management and research 2019; 11:1189-1197. http://www.ncbi.nlm.nih.gov/pubmed/?term=30787638
  4. Zhang J, Li Q, Wu Y et al. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cell communication and signaling : CCS 2019; 17:15. http://www.ncbi.nlm.nih.gov/pubmed/?term=30786890
  5. Gobel A, Breining D, Rauner M et al. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell death & disease 2019; 10:91. http://www.ncbi.nlm.nih.gov/pubmed/?term=30692522
  6. Alkreathy HM, Alkhatib MH, Al Musaddi SA et al. Enhanced anti-tumor activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma. Clin Exp Pharmacol Physiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30724380
  7. Xia DK, Hu ZG, Tian YF, Zeng FJ. Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials. Drug design, development and therapy 2019; 13:405-422. http://www.ncbi.nlm.nih.gov/pubmed/?term=30774306
  8. Kim JH, Chung BI. Re: Timu J. Murtola, Hemo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701. European urology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738708
  9. Murtola TJ, Syvala H, Riikonen J. Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701. European urology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738709
  10. Zaki Husain Rizvi S, Ali Shah F, Khan N et al. Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model. Int J Pharm 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753932
  11. Bourgier C, Auperin A, Rivera S et al. Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients with Head and Neck Cancer: Results of the Biology-Driven Phase Ii Clinical Trial Pravacur. International journal of radiation oncology, biology, physics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776452
  12. Lee S, Lee HJ, Kang H et al. Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect. Journal of clinical medicine 2019; 8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30754707
  13. Kotti A, Holmqvist A, Albertsson M, Sun XF. Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study. Journal of geriatric oncology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30692020
  14. Hopkins RJ, Young RP. Mevalonate signaling, COPD and cancer: the statins and beyond. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30787037
  15. Yun UJ, Lee JH, Shim J et al. Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway. Lab Invest 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700846
  16. Riis AH, Erichsen R, Ostenfeld EB et al. Validating registry data on statins prescriptions by blood measurements. Pharmacoepidemiol Drug Saf 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30779395
  17. Cho Y, Kim MS, Nam CM, Kang ES. Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Scientific reports 2019; 9:1467. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728421
  18. Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745071

Children

  1. Di Taranto MD, de Falco R, Guardamagna O et al. Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio. Clin Chem Lab Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30710474 

Cost-effectiveness

  1. He X, Wang Y, Cong H et al. Impact of Optimal Medical Therapy at Discharge on 1-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China. Clinical therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30770126
  2. Cardoso R, Blumenthal RS, Kopecky S et al. How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clinic proceedings 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737057
  3. Limwattananon C, Waleekhachonloet O. Access to and price trends of antidiabetic, antihypertensive, and antilipidemic drugs in outpatient settings of the Universal Coverage Scheme in Thailand. PLoS One 2019; 14:e0211759. http://www.ncbi.nlm.nih.gov/pubmed/?term=30785916

CVD

  1. Sharma A, Sun JL, Lokhnygina Y et al. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30739657
  2. Yeh JJ, Lin CL, Hsu CY et al. Associations between statins and coronary artery disease and stroke risks in patients with asthma-chronic obstructive pulmonary disease overlap syndrome: A time-dependent regression study. Atherosclerosis 2019; 283:61-68. http://www.ncbi.nlm.nih.gov/pubmed/?term=30782562
  3. Wolska-Krawczyk M, Drunck M, Behnke S, Reith W. Risk Factors for Restenosis After Stenting or Angioplasty of Vertebral Artery Origin : Results of Short-term and Long-term Follow-up. Clinical neuroradiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783694
  4. Kang DO, Park Y, Seo JH et al. Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745001
  5. Park SJ, Park H, Kang D et al. Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service. PLoS One 2019; 14:e0210498. http://www.ncbi.nlm.nih.gov/pubmed/?term=30699150

Endothelium/inflammation

  1. Solberg OG, Stavem K, Ragnarsson A et al. Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30790446
  2. Lee HR, Jo MK, Park KY et al. Anti-TNF effect of combined pravastatin and cilostazol treatment in an in vivo mouse model. Immunopharmacology and immunotoxicology 2019:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714456
  3. Kang DO, Park Y, Seo JH et al. Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745001
  4. Lee KR, Midgette Y, Shah R. Fish Oil Derived Omega 3 Fatty Acids Suppress Adipose NLRP3 Inflammasome Signaling in Human Obesity. Journal of the Endocrine Society 2019; 3:504-515. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788452
  5. Han Q, Liu Q, Zhang H et al. Simvastatin Improves Cardiac Hypertrophy in Diabetic Rats by Attenuation of Oxidative Stress and Inflammation Induced by Calpain-1-Mediated Activation of Nuclear Factor-kappaB (NF-kappaB). Medical science monitor : international medical journal of experimental and clinical research 2019; 25:1232-1241. http://www.ncbi.nlm.nih.gov/pubmed/?term=30767945
  6. Perucha E, Melchiotti R, Bibby JA et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nature communications 2019; 10:498. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700717
  7. Wildes TJ, Grippin A, Fasanya H et al. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. Vaccine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30686636

Ethnicity

  1. Riestenberg RA, Furman A, Cowen A et al. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. Am Heart J 2018; 209:79-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685678
  2. Han SN, Yang WH, Yin JJ et al. Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination. Am J Cardiovasc Drugs 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714088
  3. Lu J, Lu Y, Yang H et al. Characteristics of High Cardiovascular Risk in 1.7 Million Chinese Adults. Annals of internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776800
  4. Jun JE, Cho IJ, Han K et al. Statins for primary prevention in adults aged 75 years and older: A nationwide population-based case-control study. Atherosclerosis 2019; 283:28-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=30772771
  5. Yeh JJ, Lin CL, Hsu CY et al. Associations between statins and coronary artery disease and stroke risks in patients with asthma-chronic obstructive pulmonary disease overlap syndrome: A time-dependent regression study. Atherosclerosis 2019; 283:61-68. http://www.ncbi.nlm.nih.gov/pubmed/?term=30782562
  6. Colantonio LD, Monda KL, Rosenson RS et al. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria. Cardiovasc Drugs Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30746585
  7. Blom DJ, Raal F, Amod A et al. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovascular journal of Africa 2019; 30:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30720848
  8. He X, Wang Y, Cong H et al. Impact of Optimal Medical Therapy at Discharge on 1-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China. Clinical therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30770126
  9. Kang DO, Park Y, Seo JH et al. Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745001
  10. Trong HN, Tat TN, Anh TTN et al. Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis: The Vietnamese Experience. Open access Macedonian journal of medical sciences 2019; 7:237-242. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745969
  11. Limwattananon C, Waleekhachonloet O. Access to and price trends of antidiabetic, antihypertensive, and antilipidemic drugs in outpatient settings of the Universal Coverage Scheme in Thailand. PLoS One 2019; 14:e0211759. http://www.ncbi.nlm.nih.gov/pubmed/?term=30785916
  12. Song B, Cao Y, Pei L et al. Efficacy of High-intensity Statin Use for Transient Ischemic Attack Patients with Positive Diffusion-weighted Imaging. Scientific reports 2019; 9:1173. http://www.ncbi.nlm.nih.gov/pubmed/?term=30718523
  13. Rattanachotphanit T, Limwattananon C, Waleekhachonloet O. Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand. Therapeutic advances in drug safety 2019; 10:2042098618820502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728944
  14. Elnaem MH, Mohamed MHN, Huri HZ, Shah ASM. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Therapeutics and clinical risk management 2019; 15:137-145. http://www.ncbi.nlm.nih.gov/pubmed/?term=30705590

FH

  1. Rodriguez-Jimenez C, Gomez-Coronado D, Frias Vargas M et al. A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition. Atherosclerosis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30777337
  2. Ginsberg HN, Tuomilehto J, Hovingh GK et al. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30734207
  3. Di Taranto MD, de Falco R, Guardamagna O et al. Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio. Clin Chem Lab Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30710474
  4. Leggiero E, Labruna G, Iaffaldano L et al. Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice. Gene therapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700805
  5. Ogura M. [Familial Hypercholesterolemia and Its Related Molecules]. Rinsho Byori 2016; 64:657-666. http://www.ncbi.nlm.nih.gov/pubmed/?term=30695320
  6. Gaisenok OV, Kurnosov PA, Leonov AS, Zateeyshikov DA. Screening of familial hypercholesterolemia among patients in age under 40 years old exposed by duplex scanning of carotid arteries, by the local registry data. Ter Arkh 2018; 90:37-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=30701733

Genetics

  1. Rodriguez-Jimenez C, Gomez-Coronado D, Frias Vargas M et al. A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition. Atherosclerosis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30777337
  2. Leggiero E, Labruna G, Iaffaldano L et al. Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice. Gene therapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700805
  3. Chan JCM, Ng MH, Wong RSM, Tomlinson B. A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana. Journal of clinical pharmacy and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714173

Guidelines

  1. Li B, Salata K, de Mestral C et al. Perceptions of Canadian vascular surgeons toward pharmacologic risk reduction in patients with peripheral artery disease: 2018 update. Annals of vascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30771465
  2. Ceska R, Taborsky M, Vrablik M. Consensus statement of professional associations on prescribing of PCSK9-inhibitors. Vnitr Lek 2019; 64:1131-1136. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704246

LDL- related parameters

  1. Blom DJ, Raal F, Amod A et al. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovascular journal of Africa 2019; 30:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30720848
  2. Altunkeser BB, Tuncez A, Ozturk B et al. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome. Coronary artery disease 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30741744
  3. Shin J, Chung JW, Jang HS et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2019:2047487319830503. http://www.ncbi.nlm.nih.gov/pubmed/?term=30782002
  4. Sharpton RA, Laucka PJ, McKeller RN et al. The Impact of Obesity on the Efficacy of Simvastatin for Lowering Low-Density Lipoprotein Cholesterol in a Veteran Population. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2017; 34:41-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766266
  5. Shapiro MD, Minnier J, Tavori H et al. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc 2019; 8:e010932. http://www.ncbi.nlm.nih.gov/pubmed/?term=30755061
  6. Hsu H, Hsu P, Cheng MH et al. Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan. J Atheroscler Thromb 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30726792
  7. Endo H, Dohi T, Miyauchi K et al. Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737184
  8. Kunlamas Y, Areepium N, Ariyachaipanich A, Bunditanukul K. Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention. Journal of pharmacy practice 2019:897190019825915. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776951
  9. Zhao Z, Du S, Shen S et al. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. Medicine (Baltimore) 2019; 98:e14400. http://www.ncbi.nlm.nih.gov/pubmed/?term=30732185
  10. Riis AH, Erichsen R, Ostenfeld EB et al. Validating registry data on statins prescriptions by blood measurements. Pharmacoepidemiol Drug Saf 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30779395
  11. Dansinger M, Williams PT, Superko HR, Schaefer EJ. The importance of cholesterol follow-up testing under current statin treatment guidelines. Prev Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30742874
  12. Blaha V. Lipoprotein(a) - the cardiovascular risk factor: significance and therapeutic possibilities. Vnitr Lek 2019; 64:1160-1168. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704252

Lifestyle

  1. Scognamiglio M, Costa D, Sorriento A, Napoli C. Current therapy and nutraceuticals for the treatment of patients with dyslipidemias. Current pharmaceutical design 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30706799
  2. Hwang YC, Jun JE, Jeong IK et al. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30688048
  3. Sharpton RA, Laucka PJ, McKeller RN et al. The Impact of Obesity on the Efficacy of Simvastatin for Lowering Low-Density Lipoprotein Cholesterol in a Veteran Population. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2017; 34:41-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766266

Meta-analyses

  1. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J 2019; 210:18-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=30716508
  2. Khan SU, Khan MU, Rahman H et al. A Bayesian network meta-analysis of preventive strategies for contrast-induced nephropathy after cardiac catheterization. Cardiovascular revascularization medicine : including molecular interventions 2019; 20:29-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30757995
  3. Xia DK, Hu ZG, Tian YF, Zeng FJ. Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials. Drug design, development and therapy 2019; 13:405-422. http://www.ncbi.nlm.nih.gov/pubmed/?term=30774306
  4. Shin J, Chung JW, Jang HS et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2019:2047487319830503. http://www.ncbi.nlm.nih.gov/pubmed/?term=30782002
  5. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393:407-415. http://www.ncbi.nlm.nih.gov/pubmed/?term=30712900
  6. Cheung BMY, Lam KSL. Never too old for statin treatment? Lancet 2019; 393:379-380. http://www.ncbi.nlm.nih.gov/pubmed/?term=30712888
  7. Yang S, Gu YY, Jing F et al. The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Medical science monitor : international medical journal of experimental and clinical research 2019; 25:590-597. http://www.ncbi.nlm.nih.gov/pubmed/?term=30698163
  8. Zhao Z, Du S, Shen S et al. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. Medicine (Baltimore) 2019; 98:e14400. http://www.ncbi.nlm.nih.gov/pubmed/?term=30732185
  9. Warendorf JK, Vrancken A, van Eijk RPA et al. Statins do not increase risk of polyneuropathy: A case-control study and literature review. Neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737334
  10. Sharp AJ, Patel N, Reeves BC et al. Pharmacological interventions for the prevention of contrast-induced acute kidney injury in high-risk adult patients undergoing coronary angiography: a systematic review and meta-analysis of randomised controlled trials. Open heart 2019; 6:e000864. http://www.ncbi.nlm.nih.gov/pubmed/?term=30774964

Metabolic Syndrome - Diabetes

  1. Arbel R, Hammerman A, Azuri J. Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30711247
  2. Puttarajappa CM, Tevar AD, Hariharan S et al. Screening Coronary Angiography in Patients with Long-Standing Diabetes Mellitus undergoing Kidney Transplant Evaluation. Clinical transplantation 2019:e13501. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776157
  3. Haque T, Bhaheetharan S, Khan BV. Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes? Expert review of endocrinology & metabolism 2010; 5:835-837. http://www.ncbi.nlm.nih.gov/pubmed/?term=30780833
  4. Hsu H, Hsu P, Cheng MH et al. Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan. J Atheroscler Thromb 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30726792
  5. Jose Gagliardino J, Arechavaleta R, Goldberg Eliaschewitz F et al. Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes. Journal of clinical & translational endocrinology 2019; 15:76-80. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788219
  6. Vincent R, Kim J, Ahmed T, Patel V. Pharmacist Statin Prescribing Initiative in Diabetic Patients at an Internal Medicine Resident Clinic. Journal of pharmacy practice 2019:897190018824820. http://www.ncbi.nlm.nih.gov/pubmed/?term=30696337
  7. Elnaem MH, Mohamed MHN, Huri HZ, Shah ASM. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Therapeutics and clinical risk management 2019; 15:137-145. http://www.ncbi.nlm.nih.gov/pubmed/?term=30705590
  8. Hori E, Kikuchi C, Imaeda K et al. [Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia]. Yakugaku Zasshi 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30773524
  9. Li FL, Wan X, Wang X et al. [Simvastatin prevented myocardium of diabetes rats from apoptosis through inhibition of oxidative stress]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2018; 34:422-426 469. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788922

New Treatments

  1. Ogata A, Oho K, Matsumoto N et al. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. Acta neurochirurgica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30729307
  2. Yao X, Gersh BJ, Lopez-Jimenez F et al. Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice? Am Heart J 2018; 209:54-62. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685675
  3. Arbel R, Hammerman A, Azuri J. Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30711247
  4. Garcia R, Burkle J. New and Future Parenteral Therapies for the Management of Lipid Disorders. Arch Med Res 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30739730
  5. Park JG, Oh GT. Current pharmacotherapies for atherosclerotic cardiovascular diseases. Archives of pharmacal research 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30725249
  6. Colantonio LD, Monda KL, Rosenson RS et al. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria. Cardiovasc Drugs Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30746585
  7. Ginsberg HN, Tuomilehto J, Hovingh GK et al. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30734207
  8. Hadjiphilippou S, Ray KK. Cholesterol-Lowering Agents. Circulation research 2019; 124:354-363. http://www.ncbi.nlm.nih.gov/pubmed/?term=30702991
  9. Marco-Benedi V, Jarauta E, Perez-Calahorra S et al. Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors. Clin Investig Arterioscler 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738610
  10. Nishikido T, Ray KK. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. Frontiers in cardiovascular medicine 2018; 5:199. http://www.ncbi.nlm.nih.gov/pubmed/?term=30761308
  11. Yokote K, Yamashita S, Arai H et al. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-alpha Modulator (SPPARMalpha), in Dyslipidemic Patients with Renal Impairment. Int J Mol Sci 2019; 20. http://www.ncbi.nlm.nih.gov/pubmed/?term=30736366
  12. Shapiro MD, Minnier J, Tavori H et al. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc 2019; 8:e010932. http://www.ncbi.nlm.nih.gov/pubmed/?term=30755061
  13. Wang X, Luo S, Gan X et al. Safety and efficacy of ETC-1002 in hypercholesterolemic patients: a meta-analysis of randomized controlled trials. Kardiol Pol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30740643
  14. Cardoso R, Blumenthal RS, Kopecky S et al. How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clinic proceedings 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737057
  15. Del Vecchio L, Baragetti I, Locatelli F. New agents to reduce cholesterol levels: implications for nephrologists. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753594
  16. Mitchell KA, Moore JX, Rosenson RS et al. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. PLoS One 2019; 14:e0210808. http://www.ncbi.nlm.nih.gov/pubmed/?term=30726226
  17. Elamin AFM, Grafton-Clarke C, Wen Chen K et al. Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study. Postgraduate medical journal 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30709868
  18. Lankin VZ, Tikhaze AK, Viigimaa M, Chazova Icapital Ie C. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases. Ter Arkh 2018; 90:27-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30701731
  19. Ceska R, Taborsky M, Vrablik M. Consensus statement of professional associations on prescribing of PCSK9-inhibitors. Vnitr Lek 2019; 64:1131-1136. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704246

Other

  1. Riestenberg RA, Furman A, Cowen A et al. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. Am Heart J 2018; 209:79-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685678
  2. Luscher TF, Davies A. Inclusion of multiple inappropriate studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome: editor's response. Eur Heart J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783647
  3. Turgeon RD, Althouse AD. Inappropriate inclusion of multiple studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome. Eur Heart J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783662
  4. Rosenblum JM, Lovasik BP, Hunting JC et al. Predicted Risk of Mortality Score predicts 30-day readmission after coronary artery bypass grafting. General thoracic and cardiovascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30734216
  5. Correction to: Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness; DOI: 10.1089/jpm.2016.0489. Journal of palliative medicine 2019; 22:351. http://www.ncbi.nlm.nih.gov/pubmed/?term=30794488
  6. Pertiwi K, Kok DE, Wanders AJ et al. Circulating n-3 fatty acids and linoleic acid as indicators of dietary fatty acid intake in post-myocardial infarction patients. Nutrition, metabolism, and cardiovascular diseases : NMCD 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30718141

PAD and statins

  1. Li B, Salata K, de Mestral C et al. Perceptions of Canadian vascular surgeons toward pharmacologic risk reduction in patients with peripheral artery disease: 2018 update. Annals of vascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30771465
  2. Parmar GM, Novak Z, Spangler E et al. Statin use improves limb salvage after intervention for peripheral arterial disease. Journal of vascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30718113

Pleiotropic effects of statins

  1. Lee H, Lee H, Na CB, Park JB. The effects of simvastatin on cellular viability, stemness and osteogenic differentiation using 3-dimensional cultures of stem cells and osteoblast-like cells. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30729760
  2. Sroda-Pomianek K, Michalak K, Palko-Labuz A et al. Simvastatin Strongly Augments Proapoptotic, Anti-inflammatory and Cytotoxic Activity of Oxicam Derivatives in Doxorubicin-resistant Colon Cancer Cells. Anticancer research 2019; 39:727-734. http://www.ncbi.nlm.nih.gov/pubmed/?term=30711951
  3. Terabe K, Takahashi N, Cobb M et al. Simvastatin promotes restoration of chondrocyte morphology and phenotype. Archives of biochemistry and biophysics 2019; 665:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776329
  4. Chen Q, Zhang J, Feng H, Chen Z. An update on statins: Pleiotropic effect performed in intracerebral hemorrhage. Atherosclerosis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30712828
  5. Husain MI, Chaudhry IB, Khoso AB et al. Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial. BJPsych open 2019; 5:e13. http://www.ncbi.nlm.nih.gov/pubmed/?term=30762508
  6. Raafat SN. Response to: Letter to the editor: The sole and combined effect of simvastatin and platelet rich fibrin as a filling material in induced bone defect in tibia of albino rats. Bone 2019; 120:534. http://www.ncbi.nlm.nih.gov/pubmed/?term=30711057
  7. Calvillo-Arguelles O, Abdel-Qadir H, Michalowska M et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Can J Cardiol 2019; 35:153-159. http://www.ncbi.nlm.nih.gov/pubmed/?term=30760421
  8. Kaleli-Durman D, Alp-Yildirim FI, Ozdemir O, Uydes-Dogan BS. Relaxant Effect of Atorvastatin on Isolated Rat Gastric Fundus Strips: Implications for Ca2+ signalling mechanisms. Canadian journal of physiology and pharmacology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30730760
  9. Li K, Si-Tu J, Qiu J et al. Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study. Cancer management and research 2019; 11:1189-1197. http://www.ncbi.nlm.nih.gov/pubmed/?term=30787638
  10. Khan SU, Khan MU, Rahman H et al. A Bayesian network meta-analysis of preventive strategies for contrast-induced nephropathy after cardiac catheterization. Cardiovascular revascularization medicine : including molecular interventions 2019; 20:29-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30757995
  11. Gobel A, Breining D, Rauner M et al. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell death & disease 2019; 10:91. http://www.ncbi.nlm.nih.gov/pubmed/?term=30692522
  12. Feng X, Wang C, Gu Z et al. Rosuvastatin Regulates Odontoblast Differentiation by Suppressing NF-kappaB Activation in an Inflammatory Environment. Cellular reprogramming 2019; 21:18-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=30735076
  13. Alkreathy HM, Alkhatib MH, Al Musaddi SA et al. Enhanced anti-tumor activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma. Clin Exp Pharmacol Physiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30724380
  14. Marco-Benedi V, Jarauta E, Perez-Calahorra S et al. Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors. Clin Investig Arterioscler 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738610
  15. Xia DK, Hu ZG, Tian YF, Zeng FJ. Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials. Drug design, development and therapy 2019; 13:405-422. http://www.ncbi.nlm.nih.gov/pubmed/?term=30774306
  16. Kim JH, Chung BI. Re: Timu J. Murtola, Hemo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701. European urology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738708
  17. Murtola TJ, Syvala H, Riikonen J. Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701. European urology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738709
  18. Sun W, Pan R, Song J, Sun H. The effects of simvastatin preconditioning on the expression of caspase-3 after myocardial ischemia reperfusion injury in rats. Experimental and therapeutic medicine 2019; 17:2230-2234. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783483
  19. Haque T, Bhaheetharan S, Khan BV. Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes? Expert review of endocrinology & metabolism 2010; 5:835-837. http://www.ncbi.nlm.nih.gov/pubmed/?term=30780833
  20. Bourgier C, Auperin A, Rivera S et al. Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients with Head and Neck Cancer: Results of the Biology-Driven Phase Ii Clinical Trial Pravacur. International journal of radiation oncology, biology, physics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776452
  21. Nenna A, Spadaccio C, Lusini M et al. Preoperative atorvastatin reduces bleeding and blood transfusions in patients undergoing elective isolated aortic valve replacement. Interact Cardiovasc Thorac Surg 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753487
  22. Lee S, Lee HJ, Kang H et al. Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect. Journal of clinical medicine 2019; 8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30754707
  23. Kotti A, Holmqvist A, Albertsson M, Sun XF. Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study. Journal of geriatric oncology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30692020
  24. Hopkins RJ, Young RP. Mevalonate signaling, COPD and cancer: the statins and beyond. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30787037
  25. Harshman SG, Shea MK, Fu X et al. Atorvastatin Decreases Renal Menaquinone-4 Formation in C57BL/6 Male Mice. The Journal of nutrition 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753659
  26. Hosseinzadeh A, Bahrampour Juybari K, Kamarul T, Sharifi AM. Protective effects of atorvastatin on high glucose-induced oxidative stress and mitochondrial apoptotic signaling pathways in cultured chondrocytes. Journal of physiology and biochemistry 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30796627
  27. Lee S, Kim DH, Youn YN et al. Rosuvastatin attenuates bioprosthetic heart valve calcification. The Journal of thoracic and cardiovascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738596
  28. Joshi SS, Ruth K, Smaldone MC et al. Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy. Kidney cancer 2018; 2:47-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=30740579
  29. Yun UJ, Lee JH, Shim J et al. Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway. Lab Invest 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700846
  30. Bruder-Nascimento T, Callera GE, Montezano AC et al. Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress. Life sciences 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30721707
  31. Han Q, Liu Q, Zhang H et al. Simvastatin Improves Cardiac Hypertrophy in Diabetic Rats by Attenuation of Oxidative Stress and Inflammation Induced by Calpain-1-Mediated Activation of Nuclear Factor-kappaB (NF-kappaB). Medical science monitor : international medical journal of experimental and clinical research 2019; 25:1232-1241. http://www.ncbi.nlm.nih.gov/pubmed/?term=30767945
  32. Yang S, Gu YY, Jing F et al. The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Medical science monitor : international medical journal of experimental and clinical research 2019; 25:590-597. http://www.ncbi.nlm.nih.gov/pubmed/?term=30698163
  33. Perucha E, Melchiotti R, Bibby JA et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nature communications 2019; 10:498. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700717
  34. Witsch J, Al-Mufti F, Connolly ES et al. Statins and perihemorrhagic edema in patients with spontaneous intracerebral hemorrhage. Neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728307
  35. Trong HN, Tat TN, Anh TTN et al. Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis: The Vietnamese Experience. Open access Macedonian journal of medical sciences 2019; 7:237-242. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745969
  36. Tsur A, Kalish F, Burgess J et al. Pravastatin improves fetal survival in mice with a partial deficiency of heme oxygenase-1. Placenta 2019; 75:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30712660
  37. Park SJ, Park H, Kang D et al. Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service. PLoS One 2019; 14:e0210498. http://www.ncbi.nlm.nih.gov/pubmed/?term=30699150
  38. Oh TK, Chang CB, Shin HJ et al. Association between perioperative statin use and postoperative pain after total knee arthroplasty. Regional anesthesia and pain medicine 2019; 44:221-226. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700616
  39. Masajtis-Zagajewska A, Nowicki M. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Ren Fail 2018; 40:700-709. http://www.ncbi.nlm.nih.gov/pubmed/?term=30741616
  40. Cho Y, Kim MS, Nam CM, Kang ES. Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Scientific reports 2019; 9:1467. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728421
  41. Schulz J, Vollmer C, Truse R et al. Effect of Pravastatin Pretreatment and Hypercapnia on Intestinal Microvascular Oxygenation and Blood Flow During Sepsis. Shock 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30724816
  42. Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745071
  43. Wildes TJ, Grippin A, Fasanya H et al. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. Vaccine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30686636
  44. Chiadika SM, Shobayo FO, Naqvi SH et al. Lower femoral neck bone mineral density (BMD) in elderly women not on statins. Women & health 2019:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30721115
  45. Wan X, Wang X, Li FL et al. [Protective effect of simvastatin on kidney of rats with diabetes mellitus and the possible mechanism]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2018; 34:313-317. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788938
  46. Huai J, Yang Z, Yi YH, Wang GJ. [Changes of Rheb gene and protein expression in preeclampsia-like mouse model treated with pravastatin]. Zhonghua fu chan ke za zhi 2019; 54:38-43. http://www.ncbi.nlm.nih.gov/pubmed/?term=30695905

Primary Prevention

  1. Lu J, Lu Y, Yang H et al. Characteristics of High Cardiovascular Risk in 1.7 Million Chinese Adults. Annals of internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776800
  2. Jun JE, Cho IJ, Han K et al. Statins for primary prevention in adults aged 75 years and older: A nationwide population-based case-control study. Atherosclerosis 2019; 283:28-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=30772771
  3. Fernandez-Ruiz I. Statin efficacy in primary CVD prevention might diminish with patient age. Nat Rev Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783252
  4. Elnaem MH, Mohamed MHN, Huri HZ, Shah ASM. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Therapeutics and clinical risk management 2019; 15:137-145. http://www.ncbi.nlm.nih.gov/pubmed/?term=30705590

Registry data

  1. Petrov I, Dumitrescu A, Snejdrlova M et al. Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study. Adv Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30758746
  2. Yeh JJ, Lin CL, Hsu CY et al. Associations between statins and coronary artery disease and stroke risks in patients with asthma-chronic obstructive pulmonary disease overlap syndrome: A time-dependent regression study. Atherosclerosis 2019; 283:61-68. http://www.ncbi.nlm.nih.gov/pubmed/?term=30782562
  3. Marcum ZA, Walker RL, Jones BL et al. Patterns of antihypertensive and statin adherence prior to dementia: findings from the adult changes in thought study. BMC geriatrics 2019; 19:41. http://www.ncbi.nlm.nih.gov/pubmed/?term=30764775
  4. Fan L, Wang Y, Liu X, Guan X. Association between statin use and herpes zoster: systematic review and meta-analysis. BMJ Open 2019; 9:e022897. http://www.ncbi.nlm.nih.gov/pubmed/?term=30765397
  5. Li K, Si-Tu J, Qiu J et al. Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study. Cancer management and research 2019; 11:1189-1197. http://www.ncbi.nlm.nih.gov/pubmed/?term=30787638
  6. Wolska-Krawczyk M, Drunck M, Behnke S, Reith W. Risk Factors for Restenosis After Stenting or Angioplasty of Vertebral Artery Origin : Results of Short-term and Long-term Follow-up. Clinical neuroradiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783694
  7. Kelly KE, Jiroutek MR, Lewis K, Zagar B. Assessing Changes in Statin Prescribing Patterns Surrounding the 2013 American College of Cardiology/American Heart Association Lipid Guidelines. Clinical therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30686571
  8. Rosenblum JM, Lovasik BP, Hunting JC et al. Predicted Risk of Mortality Score predicts 30-day readmission after coronary artery bypass grafting. General thoracic and cardiovascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30734216
  9. Markossian TW, Kramer HJ, Burge NJ et al. Statin use among Veterans with dialysis-dependent chronic kidney disease. Hemodialysis international. International Symposium on Home Hemodialysis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30779455
  10. Thomson SR, Chogtu B, Shetty R, Devasia T. Analysis of glycemic status in diabetes-naive patients on statins: A hospital-based cross-sectional study. Indian journal of pharmacology 2018; 50:320-325. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783324
  11. Bourgier C, Auperin A, Rivera S et al. Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients with Head and Neck Cancer: Results of the Biology-Driven Phase Ii Clinical Trial Pravacur. International journal of radiation oncology, biology, physics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776452
  12. Hsu H, Hsu P, Cheng MH et al. Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan. J Atheroscler Thromb 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30726792
  13. Al'Aref SJ, Su A, Gransar H et al. A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography. Journal of cardiovascular computed tomography 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745132
  14. Jose Gagliardino J, Arechavaleta R, Goldberg Eliaschewitz F et al. Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes. Journal of clinical & translational endocrinology 2019; 15:76-80. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788219
  15. Kotti A, Holmqvist A, Albertsson M, Sun XF. Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study. Journal of geriatric oncology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30692020
  16. Kunlamas Y, Areepium N, Ariyachaipanich A, Bunditanukul K. Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention. Journal of pharmacy practice 2019:897190019825915. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776951
  17. Huynh T, Lecca P, Montigny M et al. Ten-Year Statin Adherence in Survivors of ST-Segment Elevation Myocardial Infarction. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 2018; 25:e63-e77. http://www.ncbi.nlm.nih.gov/pubmed/?term=30725543
  18. Parmar GM, Novak Z, Spangler E et al. Statin use improves limb salvage after intervention for peripheral arterial disease. Journal of vascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30718113
  19. Rodriguez F, Maron DJ, Knowles JW et al. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA cardiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30758506
  20. Riis AH, Erichsen R, Ostenfeld EB et al. Validating registry data on statins prescriptions by blood measurements. Pharmacoepidemiol Drug Saf 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30779395
  21. Limwattananon C, Waleekhachonloet O. Access to and price trends of antidiabetic, antihypertensive, and antilipidemic drugs in outpatient settings of the Universal Coverage Scheme in Thailand. PLoS One 2019; 14:e0211759. http://www.ncbi.nlm.nih.gov/pubmed/?term=30785916
  22. Park SJ, Park H, Kang D et al. Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service. PLoS One 2019; 14:e0210498. http://www.ncbi.nlm.nih.gov/pubmed/?term=30699150
  23. Elamin AFM, Grafton-Clarke C, Wen Chen K et al. Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study. Postgraduate medical journal 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30709868
  24. Cho Y, Kim MS, Nam CM, Kang ES. Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Scientific reports 2019; 9:1467. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728421
  25. Song B, Cao Y, Pei L et al. Efficacy of High-intensity Statin Use for Transient Ischemic Attack Patients with Positive Diffusion-weighted Imaging. Scientific reports 2019; 9:1173. http://www.ncbi.nlm.nih.gov/pubmed/?term=30718523
  26. Gaisenok OV, Kurnosov PA, Leonov AS, Zateeyshikov DA. Screening of familial hypercholesterolemia among patients in age under 40 years old exposed by duplex scanning of carotid arteries, by the local registry data. Ter Arkh 2018; 90:37-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=30701733
  27. Rattanachotphanit T, Limwattananon C, Waleekhachonloet O. Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand. Therapeutic advances in drug safety 2019; 10:2042098618820502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728944
  28. Elnaem MH, Mohamed MHN, Huri HZ, Shah ASM. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Therapeutics and clinical risk management 2019; 15:137-145. http://www.ncbi.nlm.nih.gov/pubmed/?term=30705590
  29. Chiadika SM, Shobayo FO, Naqvi SH et al. Lower femoral neck bone mineral density (BMD) in elderly women not on statins. Women & health 2019:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30721115  

Renal Disease

  1. Khan SU, Khan MU, Rahman H et al. A Bayesian network meta-analysis of preventive strategies for contrast-induced nephropathy after cardiac catheterization. Cardiovascular revascularization medicine : including molecular interventions 2019; 20:29-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30757995
  2. Puttarajappa CM, Tevar AD, Hariharan S et al. Screening Coronary Angiography in Patients with Long-Standing Diabetes Mellitus undergoing Kidney Transplant Evaluation. Clinical transplantation 2019:e13501. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776157
  3. Markossian TW, Kramer HJ, Burge NJ et al. Statin use among Veterans with dialysis-dependent chronic kidney disease. Hemodialysis international. International Symposium on Home Hemodialysis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30779455
  4. Yokote K, Yamashita S, Arai H et al. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-alpha Modulator (SPPARMalpha), in Dyslipidemic Patients with Renal Impairment. Int J Mol Sci 2019; 20. http://www.ncbi.nlm.nih.gov/pubmed/?term=30736366
  5. Lui DTW, Lee ACH, Yap DYH et al. A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685233
  6. Joshi SS, Ruth K, Smaldone MC et al. Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy. Kidney cancer 2018; 2:47-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=30740579
  7. Sharp AJ, Patel N, Reeves BC et al. Pharmacological interventions for the prevention of contrast-induced acute kidney injury in high-risk adult patients undergoing coronary angiography: a systematic review and meta-analysis of randomised controlled trials. Open heart 2019; 6:e000864. http://www.ncbi.nlm.nih.gov/pubmed/?term=30774964
  8. Masajtis-Zagajewska A, Nowicki M. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Ren Fail 2018; 40:700-709. http://www.ncbi.nlm.nih.gov/pubmed/?term=30741616

Reviews

  1. Petrov I, Dumitrescu A, Snejdrlova M et al. Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study. Adv Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30758746
  2. Han SN, Yang WH, Yin JJ et al. Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination. Am J Cardiovasc Drugs 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714088
  3. Garcia R, Burkle J. New and Future Parenteral Therapies for the Management of Lipid Disorders. Arch Med Res 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30739730
  4. Park JG, Oh GT. Current pharmacotherapies for atherosclerotic cardiovascular diseases. Archives of pharmacal research 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30725249
  5. Waters DD, Hsue PY. Lipid Abnormalities in Persons Living With HIV Infection. Can J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704819
  6. Hadjiphilippou S, Ray KK. Cholesterol-Lowering Agents. Circulation research 2019; 124:354-363. http://www.ncbi.nlm.nih.gov/pubmed/?term=30702991
  7. Climent E, Benaiges D, Pedro-Botet J. Statin treatment and increased diabetes risk. Possible mechanisms. Clin Investig Arterioscler 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737072
  8. Haque T, Bhaheetharan S, Khan BV. Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes? Expert review of endocrinology & metabolism 2010; 5:835-837. http://www.ncbi.nlm.nih.gov/pubmed/?term=30780833
  9. Strandberg TE. Challenges of a Statin Trial in Older People. J Am Geriatr Soc 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30688358
  10. Gill EA, Blaha MJ, Guyton JR. JCL roundtable: Coronary artery calcium scoring and other vascular imaging for risk assessment. J Clin Lipidol 2019; 13:4-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30773212
  11. Tournadre A. Statins, myalgia, and rhabdomyolysis. Joint Bone Spine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30735805
  12. Yun UJ, Lee JH, Shim J et al. Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway. Lab Invest 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700846
  13. Cardoso R, Blumenthal RS, Kopecky S et al. How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clinic proceedings 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737057
  14. Andrews GP, Li S, Almajaan A et al. Fixed Dose Combination Formulations: Multi-Layered Platforms Designed for the Management of Cardiovascular Disease. Molecular pharmaceutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30702301
  15. Perucha E, Melchiotti R, Bibby JA et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nature communications 2019; 10:498. http://www.ncbi.nlm.nih.gov/pubmed/?term=30700717
  16. Fernandez-Ruiz I. Statin efficacy in primary CVD prevention might diminish with patient age. Nat Rev Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783252
  17. Del Vecchio L, Baragetti I, Locatelli F. New agents to reduce cholesterol levels: implications for nephrologists. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753594
  18. Statins: increased risk of type 2 diabetes. Prescrire international 2017; 26:18-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=30730639
  19. Ogura M. [Familial Hypercholesterolemia and Its Related Molecules]. Rinsho Byori 2016; 64:657-666. http://www.ncbi.nlm.nih.gov/pubmed/?term=30695320
  20. Bezin J, Moore N. Pharmacoepidemiology of statins. Therapie 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704765
  21. Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745071
  22. Blaha V. Lipoprotein(a) - the cardiovascular risk factor: significance and therapeutic possibilities. Vnitr Lek 2019; 64:1160-1168. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704252
  23. Ceska R, Taborsky M, Vrablik M. Consensus statement of professional associations on prescribing of PCSK9-inhibitors. Vnitr Lek 2019; 64:1131-1136. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704246
  24. Karasek D. Combined lipid-lowering therapy. Vnitr Lek 2019; 64:1177-1184. http://www.ncbi.nlm.nih.gov/pubmed/?term=30704254

Safety and side effects

  1. Ho BL, Lin YJ, Lin SF et al. Statins and the risk of bleeding in patients taking dabigatran. Acta neurologica Scandinavica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30742307
  2. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J 2019; 210:18-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=30716508
  3. Cannon CP, Sanchez RJ, Klimchak AC et al. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30736965
  4. Kido K, Oyen AA, Beckmann MA, Brouse SD. Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2019; 76:206-210. http://www.ncbi.nlm.nih.gov/pubmed/?term=30689699
  5. de Dios Garcia-Diaz J, Corral-Bueno IM, Mesa-Latorre JM et al. Proprotein Convertase Subtilisin/Kexin Type 9 Antibody and Statin-Associated Autoimmune Myopathy. Annals of internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30776798
  6. Khalilieh SG, Yee KL, Sanchez RI et al. Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions. Antimicrobial agents and chemotherapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783000
  7. Shek AB, Kurbanov RD, Alieva RB et al. Personalized rosuvastatin therapy in problem patients with partial statin intolerance. Archives of medical sciences. Atherosclerotic diseases 2018; 3:e83-e89. http://www.ncbi.nlm.nih.gov/pubmed/?term=30775595
  8. Sanvee GM, Panajatovic MV, Bouitbir J, Krahenbuhl S. Mechanisms of insulin resistance by simvastatin in C2C12 myotubes and in mouse skeletal muscle. Biochem Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30796916
  9. Kim JR, Jung JA, Kim S et al. Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects. BioMed research international 2019; 2019:1365180. http://www.ncbi.nlm.nih.gov/pubmed/?term=30729119
  10. Fan L, Wang Y, Liu X, Guan X. Association between statin use and herpes zoster: systematic review and meta-analysis. BMJ Open 2019; 9:e022897. http://www.ncbi.nlm.nih.gov/pubmed/?term=30765397
  11. Tong XK, Trigiani LJ, Hamel E. High cholesterol triggers white matter alterations and cognitive deficits in a mouse model of cerebrovascular disease: benefits of simvastatin. Cell death & disease 2019; 10:89. http://www.ncbi.nlm.nih.gov/pubmed/?term=30692517
  12. Climent E, Benaiges D, Pedro-Botet J. Statin treatment and increased diabetes risk. Possible mechanisms. Clin Investig Arterioscler 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737072
  13. Vesza Z, Pires C, da Silva PM. Statin-related Lichenoid Dermatosis: An Uncommon Adverse Reaction to a Common Treatment. European journal of case reports in internal medicine 2018; 5:000844. http://www.ncbi.nlm.nih.gov/pubmed/?term=30756034
  14. Thomson SR, Chogtu B, Shetty R, Devasia T. Analysis of glycemic status in diabetes-naive patients on statins: A hospital-based cross-sectional study. Indian journal of pharmacology 2018; 50:320-325. http://www.ncbi.nlm.nih.gov/pubmed/?term=30783324
  15. Gadowski A, Owen AJ, Curtis A et al. The Effects of Statins on Physical Activity or Physical Fitness Among Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Journal of aging and physical activity 2019:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30747563
  16. Chan JCM, Ng MH, Wong RSM, Tomlinson B. A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana. Journal of clinical pharmacy and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30714173
  17. Upreti S, Fayyaz B, Bongu RP. Anti-HMG-CoA reductase myopathy, an undesirable evolution of statin induced myopathy: a case report. Journal of community hospital internal medicine perspectives 2019; 9:33-35. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788073
  18. Tournadre A. Statins, myalgia, and rhabdomyolysis. Joint Bone Spine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30735805
  19. Cardoso R, Blumenthal RS, Kopecky S et al. How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clinic proceedings 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737057
  20. Zhao Z, Du S, Shen S et al. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. Medicine (Baltimore) 2019; 98:e14400. http://www.ncbi.nlm.nih.gov/pubmed/?term=30732185
  21. Warendorf JK, Vrancken A, van Eijk RPA et al. Statins do not increase risk of polyneuropathy: A case-control study and literature review. Neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737334
  22. Mitchell KA, Moore JX, Rosenson RS et al. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. PLoS One 2019; 14:e0210808. http://www.ncbi.nlm.nih.gov/pubmed/?term=30726226
  23. Statins: increased risk of type 2 diabetes. Prescrire international 2017; 26:18-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=30730639
  24. Rattanachotphanit T, Limwattananon C, Waleekhachonloet O. Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand. Therapeutic advances in drug safety 2019; 10:2042098618820502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728944
  25. El-Ganainy SO, El-Mallah A, Abdallah D et al. A novel investigation of statins myotoxic mechanism: Effect of atorvastatin on respiratory muscles in hypoxic environment. Toxicology letters 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30735765
  26. Hori E, Kikuchi C, Imaeda K et al. [Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia]. Yakugaku Zasshi 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30773524

Stroke and CNS

  1. Chen Q, Zhang J, Feng H, Chen Z. An update on statins: Pleiotropic effect performed in intracerebral hemorrhage. Atherosclerosis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30712828
  2. Malhotra K, Safouris A, Goyal N et al. Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients: A meta-analysis. Atherosclerosis 2019; 282:75-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=30708178
  3. Yeh JJ, Lin CL, Hsu CY et al. Associations between statins and coronary artery disease and stroke risks in patients with asthma-chronic obstructive pulmonary disease overlap syndrome: A time-dependent regression study. Atherosclerosis 2019; 283:61-68. http://www.ncbi.nlm.nih.gov/pubmed/?term=30782562
  4. Taniguti EH, Ferreira YS, Stupp IJV et al. Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. Brain research bulletin 2019; 146:279-286. http://www.ncbi.nlm.nih.gov/pubmed/?term=30690060
  5. Shin J, Chung JW, Jang HS et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2019:2047487319830503. http://www.ncbi.nlm.nih.gov/pubmed/?term=30782002
  6. Yu XB, Zhang HN, Dai Y et al. Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice. Journal of affective disorders 2019; 245:939-949. http://www.ncbi.nlm.nih.gov/pubmed/?term=30699879
  7. Wei H, Yang M, Yu K et al. Atorvastatin Protects Against Cerebral Aneurysmal Degenerative Pathology by Promoting Endothelial Progenitor Cells (EPC) Mobilization and Attenuating Vascular Deterioration in a Rat Model. Medical science monitor : international medical journal of experimental and clinical research 2019; 25:928-936. http://www.ncbi.nlm.nih.gov/pubmed/?term=30710072
  8. Witsch J, Al-Mufti F, Connolly ES et al. Statins and perihemorrhagic edema in patients with spontaneous intracerebral hemorrhage. Neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728307
  9. Song B, Cao Y, Pei L et al. Efficacy of High-intensity Statin Use for Transient Ischemic Attack Patients with Positive Diffusion-weighted Imaging. Scientific reports 2019; 9:1173. http://www.ncbi.nlm.nih.gov/pubmed/?term=30718523
  10. Gaisenok OV, Kurnosov PA, Leonov AS, Zateeyshikov DA. Screening of familial hypercholesterolemia among patients in age under 40 years old exposed by duplex scanning of carotid arteries, by the local registry data. Ter Arkh 2018; 90:37-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=30701733

Triglycerides/HDL

  1. Blom DJ, Raal F, Amod A et al. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovascular journal of Africa 2019; 30:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30720848

Trials

  1. Ogata A, Oho K, Matsumoto N et al. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. Acta neurochirurgica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30729307
  2. Riestenberg RA, Furman A, Cowen A et al. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. Am Heart J 2018; 209:79-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685678
  3. Yao X, Gersh BJ, Lopez-Jimenez F et al. Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice? Am Heart J 2018; 209:54-62. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685675
  4. Sharma A, Sun JL, Lokhnygina Y et al. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30739657
  5. Shek AB, Kurbanov RD, Alieva RB et al. Personalized rosuvastatin therapy in problem patients with partial statin intolerance. Archives of medical sciences. Atherosclerotic diseases 2018; 3:e83-e89. http://www.ncbi.nlm.nih.gov/pubmed/?term=30775595
  6. Malhotra K, Safouris A, Goyal N et al. Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients: A meta-analysis. Atherosclerosis 2019; 282:75-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=30708178
  7. Husain MI, Chaudhry IB, Khoso AB et al. Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial. BJPsych open 2019; 5:e13. http://www.ncbi.nlm.nih.gov/pubmed/?term=30762508
  8. Calvillo-Arguelles O, Abdel-Qadir H, Michalowska M et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Can J Cardiol 2019; 35:153-159. http://www.ncbi.nlm.nih.gov/pubmed/?term=30760421
  9. Ballantyne CM, Manku MS, Bays HE et al. Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. Cardiology and therapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788718
  10. Colantonio LD, Monda KL, Rosenson RS et al. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria. Cardiovasc Drugs Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30746585
  11. Ginsberg HN, Tuomilehto J, Hovingh GK et al. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30734207
  12. Solberg OG, Stavem K, Ragnarsson A et al. Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30790446
  13. Marco-Benedi V, Jarauta E, Perez-Calahorra S et al. Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors. Clin Investig Arterioscler 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738610
  14. Hwang YC, Jun JE, Jeong IK et al. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30688048
  15. Lee SE, Sung JM, Andreini D et al. Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study. European heart journal cardiovascular Imaging 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30789215
  16. Bentz AJ, Netland PJ, Newman WP et al. Comparison of Cardiovascular Outcomes Between Statin Monotherapy and Fish Oil and Statin Combination Therapy in a Veteran Population. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2018; 35:26-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766323
  17. Nguyen LS, Procopi N, Salem JE et al. Relation between baseline LDL-cholesterol and cardiovascular outcomes in high cardiovascular risk hypertensive patients: A post-hoc SPRINT data analysis. Int J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685099
  18. Phillips WJ, Johnson C, Law A et al. Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. Int J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30696608
  19. Yokote K, Yamashita S, Arai H et al. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-alpha Modulator (SPPARMalpha), in Dyslipidemic Patients with Renal Impairment. Int J Mol Sci 2019; 20. http://www.ncbi.nlm.nih.gov/pubmed/?term=30736366
  20. Nenna A, Spadaccio C, Lusini M et al. Preoperative atorvastatin reduces bleeding and blood transfusions in patients undergoing elective isolated aortic valve replacement. Interact Cardiovasc Thorac Surg 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753487
  21. Gadowski A, Owen AJ, Curtis A et al. The Effects of Statins on Physical Activity or Physical Fitness Among Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Journal of aging and physical activity 2019:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30747563
  22. Shapiro MD, Minnier J, Tavori H et al. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc 2019; 8:e010932. http://www.ncbi.nlm.nih.gov/pubmed/?term=30755061
  23. Endo H, Dohi T, Miyauchi K et al. Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737184
  24. Kang DO, Park Y, Seo JH et al. Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745001
  25. Vincent R, Kim J, Ahmed T, Patel V. Pharmacist Statin Prescribing Initiative in Diabetic Patients at an Internal Medicine Resident Clinic. Journal of pharmacy practice 2019:897190018824820. http://www.ncbi.nlm.nih.gov/pubmed/?term=30696337
  26. Wang X, Luo S, Gan X et al. Safety and efficacy of ETC-1002 in hypercholesterolemic patients: a meta-analysis of randomized controlled trials. Kardiol Pol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30740643
  27. Witsch J, Al-Mufti F, Connolly ES et al. Statins and perihemorrhagic edema in patients with spontaneous intracerebral hemorrhage. Neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728307
  28. Trong HN, Tat TN, Anh TTN et al. Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis: The Vietnamese Experience. Open access Macedonian journal of medical sciences 2019; 7:237-242. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745969
  29. Mitchell KA, Moore JX, Rosenson RS et al. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. PLoS One 2019; 14:e0210808. http://www.ncbi.nlm.nih.gov/pubmed/?term=30726226
  30. Statins: increased risk of type 2 diabetes. Prescrire international 2017; 26:18-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=30730639
  31. Masajtis-Zagajewska A, Nowicki M. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Ren Fail 2018; 40:700-709. http://www.ncbi.nlm.nih.gov/pubmed/?term=30741616
  32. Lankin VZ, Tikhaze AK, Viigimaa M, Chazova Icapital Ie C. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases. Ter Arkh 2018; 90:27-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30701731
  33. Wildes TJ, Grippin A, Fasanya H et al. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. Vaccine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30686636
  34. Hori E, Kikuchi C, Imaeda K et al. [Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia]. Yakugaku Zasshi 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30773524

Women and elderly

  1. Ogata A, Oho K, Matsumoto N et al. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. Acta neurochirurgica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30729307
  2. Riestenberg RA, Furman A, Cowen A et al. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. Am Heart J 2018; 209:79-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685678
  3. Yao X, Gersh BJ, Lopez-Jimenez F et al. Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice? Am Heart J 2018; 209:54-62. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685675
  4. Sharma A, Sun JL, Lokhnygina Y et al. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30739657
  5. Shek AB, Kurbanov RD, Alieva RB et al. Personalized rosuvastatin therapy in problem patients with partial statin intolerance. Archives of medical sciences. Atherosclerotic diseases 2018; 3:e83-e89. http://www.ncbi.nlm.nih.gov/pubmed/?term=30775595
  6. Malhotra K, Safouris A, Goyal N et al. Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients: A meta-analysis. Atherosclerosis 2019; 282:75-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=30708178
  7. Husain MI, Chaudhry IB, Khoso AB et al. Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial. BJPsych open 2019; 5:e13. http://www.ncbi.nlm.nih.gov/pubmed/?term=30762508
  8. Calvillo-Arguelles O, Abdel-Qadir H, Michalowska M et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Can J Cardiol 2019; 35:153-159. http://www.ncbi.nlm.nih.gov/pubmed/?term=30760421
  9. Ballantyne CM, Manku MS, Bays HE et al. Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. Cardiology and therapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30788718
  10. Colantonio LD, Monda KL, Rosenson RS et al. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria. Cardiovasc Drugs Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30746585
  11. Ginsberg HN, Tuomilehto J, Hovingh GK et al. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30734207
  12. Solberg OG, Stavem K, Ragnarsson A et al. Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30790446
  13. Marco-Benedi V, Jarauta E, Perez-Calahorra S et al. Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors. Clin Investig Arterioscler 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30738610
  14. Hwang YC, Jun JE, Jeong IK et al. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30688048
  15. Lee SE, Sung JM, Andreini D et al. Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study. European heart journal cardiovascular Imaging 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30789215
  16. Bentz AJ, Netland PJ, Newman WP et al. Comparison of Cardiovascular Outcomes Between Statin Monotherapy and Fish Oil and Statin Combination Therapy in a Veteran Population. Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2018; 35:26-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=30766323
  17. Nguyen LS, Procopi N, Salem JE et al. Relation between baseline LDL-cholesterol and cardiovascular outcomes in high cardiovascular risk hypertensive patients: A post-hoc SPRINT data analysis. Int J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30685099
  18. Phillips WJ, Johnson C, Law A et al. Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. Int J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30696608
  19. Yokote K, Yamashita S, Arai H et al. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-alpha Modulator (SPPARMalpha), in Dyslipidemic Patients with Renal Impairment. Int J Mol Sci 2019; 20. http://www.ncbi.nlm.nih.gov/pubmed/?term=30736366
  20. Nenna A, Spadaccio C, Lusini M et al. Preoperative atorvastatin reduces bleeding and blood transfusions in patients undergoing elective isolated aortic valve replacement. Interact Cardiovasc Thorac Surg 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30753487
  21. Gadowski A, Owen AJ, Curtis A et al. The Effects of Statins on Physical Activity or Physical Fitness Among Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Journal of aging and physical activity 2019:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30747563
  22. Shapiro MD, Minnier J, Tavori H et al. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc 2019; 8:e010932. http://www.ncbi.nlm.nih.gov/pubmed/?term=30755061
  23. Endo H, Dohi T, Miyauchi K et al. Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30737184
  24. Kang DO, Park Y, Seo JH et al. Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745001
  25. Vincent R, Kim J, Ahmed T, Patel V. Pharmacist Statin Prescribing Initiative in Diabetic Patients at an Internal Medicine Resident Clinic. Journal of pharmacy practice 2019:897190018824820. http://www.ncbi.nlm.nih.gov/pubmed/?term=30696337
  26. Wang X, Luo S, Gan X et al. Safety and efficacy of ETC-1002 in hypercholesterolemic patients: a meta-analysis of randomized controlled trials. Kardiol Pol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30740643
  27. Witsch J, Al-Mufti F, Connolly ES et al. Statins and perihemorrhagic edema in patients with spontaneous intracerebral hemorrhage. Neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30728307
  28. Trong HN, Tat TN, Anh TTN et al. Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis: The Vietnamese Experience. Open access Macedonian journal of medical sciences 2019; 7:237-242. http://www.ncbi.nlm.nih.gov/pubmed/?term=30745969
  29. Mitchell KA, Moore JX, Rosenson RS et al. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. PLoS One 2019; 14:e0210808. http://www.ncbi.nlm.nih.gov/pubmed/?term=30726226
  30. Statins: increased risk of type 2 diabetes. Prescrire international 2017; 26:18-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=30730639
  31. Masajtis-Zagajewska A, Nowicki M. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Ren Fail 2018; 40:700-709. http://www.ncbi.nlm.nih.gov/pubmed/?term=30741616
  32. Lankin VZ, Tikhaze AK, Viigimaa M, Chazova Icapital Ie C. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases. Ter Arkh 2018; 90:27-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30701731
  33. Wildes TJ, Grippin A, Fasanya H et al. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. Vaccine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30686636
  34. Hori E, Kikuchi C, Imaeda K et al. [Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia]. Yakugaku Zasshi 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30773524
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.